{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"0.10","upperLimit":"0.64","value":"0.41"},{"groupId":"OG001","lowerLimit":"0.05","upperLimit":"0.61","value":"0.36"},{"groupId":"OG002","lowerLimit":"-0.20","upperLimit":"0.41","value":"0.12"},{"groupId":"OG003","lowerLimit":"0.00","upperLimit":"0.58","value":"0.32"},{"groupId":"OG004","lowerLimit":"0.09","upperLimit":"0.65","value":"0.41"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"40"},{"groupId":"OG001","value":"40"},{"groupId":"OG002","value":"42"},{"groupId":"OG003","value":"41"},{"groupId":"OG004","value":"37"}],"units":"Participants"}],"title":"% Change in P1NP"},{"categories":[{"measurements":[{"groupId":"OG001","lowerLimit":"-0.24","upperLimit":"0.39","value":"0.08"},{"groupId":"OG002","lowerLimit":"-0.22","upperLimit":"0.42","value":"0.11"},{"groupId":"OG003","lowerLimit":"-0.08","upperLimit":"0.54","value":"0.26"},{"groupId":"OG004","lowerLimit":"-0.37","upperLimit":"0.32","value":"-0.03"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"40"},{"groupId":"OG002","value":"40"},{"groupId":"OG003","value":"39"},{"groupId":"OG004","value":"35"}],"units":"Participants"}],"title":"% Change in CTX-1"},{"categories":[{"measurements":[{"groupId":"OG002","lowerLimit":"-0.08","upperLimit":"0.51","value":"0.23"},{"groupId":"OG003","lowerLimit":"-0.32","upperLimit":"0.31","value":"-0.01"},{"groupId":"OG004","lowerLimit":"-0.44","upperLimit":"0.21","value":"-0.13"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"43"},{"groupId":"OG003","value":"42"},{"groupId":"OG004","value":"38"}],"units":"Participants"}],"title":"% Change in ALP"},{"categories":[{"measurements":[{"groupId":"OG003","lowerLimit":"-0.18","upperLimit":"0.43","value":"0.13"},{"groupId":"OG004","lowerLimit":"-0.20","upperLimit":"0.44","value":"0.14"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"43"},{"groupId":"OG004","value":"39"}],"units":"Participants"}],"title":"% Change in DKK1"},{"categories":[{"measurements":[{"groupId":"OG004","lowerLimit":"0.06","upperLimit":"0.62","value":"0.37"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"39"}],"units":"Participants"}],"title":"% Change in Sclerostin"},{"denoms":[{"counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"0"}],"units":"Participants"}],"title":"% Change in RANKL:OPG"}],"denoms":[{"counts":[{"groupId":"OG000","value":"40"},{"groupId":"OG001","value":"43"},{"groupId":"OG002","value":"44"},{"groupId":"OG003","value":"43"},{"groupId":"OG004","value":"49"}],"units":"Participants"}],"description":"Secondary Objective 2: To assess whether the novel Magnetic Resonance (MR) protocol and exploratory bone biomarkers can improve detection of longitudinal changes in bone loss in patients with myeloma (new, relapsed, smouldering) and Monoclonal Gammopathy of Undetermined Significance (MGUS) during therapy, compared to Dual-energy X-ray Absorptiometry (DXA) and established bone biomarkers alone.\n\nThis particular section examined the correlation between longitudinal changes in bone turnover markers between one another (calculated as a ratio of follow-up measurement divided by baseline measurement). Spearman's rank correlation was performed for the longitudinal % change between different biomarkers, to assess the relationship between longitudinal changes in these measures.","dispersionType":"95% Confidence Interval","groups":[{"description":"% Change in measurements of CTX-1 (Type I Collagen Cross-Linked C-Telopeptide).","id":"OG000","title":"% Change in CTX-1"},{"description":"% Change in measurements of ALP (Alkaline Phosphatase).","id":"OG001","title":"% Change in ALP"},{"description":"% Change in measurements of DKK1 (Dickkopf WNT Signaling Pathway Inhibitor 1).","id":"OG002","title":"% Change in DKK1"},{"description":"% Change in measurements of sclerostin.","id":"OG003","title":"% Change in Sclerostin"},{"description":"% Change in measurements of the ratio between RANKL and OPG (osteoprotegerin).","id":"OG004","title":"% Change in RANKL:OPG"}],"paramType":"NUMBER","populationDescription":"Pooled population of participants from Groups 1 and 2 who had paired measurements of follow-up and baseline bone turnover markers.\n\nFor some rows, the total number of participants analysed are less than the overall number of participants analysed, due to assay failure of some bone biomarkers variably on individual samples.","reportingStatus":"POSTED","timeFrame":"Comparison between baseline and follow-up at 6month","title":"Secondary Outcome 2: Detect Longitudinal Changes in Bone Microarchitecture With Therapy (Correlations Between % Change in Bone Turnover Markers)","type":"SECONDARY","unitOfMeasure":"Spearman's rank correlation coefficient"}